Enzalutamide: all 198 studies that test it

Page 1 of 2. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingNCT07783282Phase 1
• Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingNCT07717268Phase 2
• Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate CancerNot yet recruitingNCT07683013Phase 1
• Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3
• A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor TherapyNot yet recruitingNCT07592910Phase 2
• A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruitingNCT07226986Phase 1/2
• Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）Not yet recruitingNCT07104643Phase 1/2
• The COSMYC Trial (COmbined Suppression of MYC)RecruitingNCT06922318Phase 2
• Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06702995Phase 1/2
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingNCT06632977Phase 2
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingNCT06616155Phase 1/2
• Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingNCT06582628Phase 2
• Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginRecruitingNCT06576037Phase 1
• Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialRecruitingNCT06499870Phase 2
• Enzalutamide Implants (Enolen) in Patients With Prostate CancerRecruitingNCT06257693Phase 1
• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06236139Phase 1/2
• Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerRecruitingNCT06228053Phase 2
• Relugolix + Enzalutamide Study in High-Risk Prostate CancerRecruitingNCT06130995Phase 1
• Combination Study of Antibiotics With Enzalutamide (PROMIZE)RecruitingNCT06126731Phase 1/2
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerRecruitingNCT06099769Phase 2
• Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06059118Phase 2
• An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic AdenocarcinomaNot yet recruitingNCT06015321Phase 2
• Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingNCT05873192Phase 2
• Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerRecruitingNCT05743621Phase 1
• Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC StageRecruitingNCT05627752Phase 2/3
• Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2
• ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).RecruitingNCT03851640Phase 3
• Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate CancerRecruitingNCT02935205Phase 1/2
• Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedNCT05730712Phase 2Results posted
• Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT05081193Phase 2Results posted
• Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)TerminatedNCT04631601Phase 1/2Results posted
• Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or EnzalutamideCompletedNCT04335682Phase 2Results posted
• Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerActive, not recruitingNCT04262154Phase 2Results posted
• A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC PatientsTerminatedNCT04237584Phase 3Results posted
• Addition of Opaganib to Androgen Antagonists in Patients With mCRPCCompletedNCT04207255Phase 2Results posted
• A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerTerminatedNCT04179864Phase 1/2Results posted
• Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)TerminatedNCT04157088Phase 2Results posted
• An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Active, not recruitingNCT04076059Phase 3Results posted
• Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsTerminatedNCT04052204Phase 1/2Results posted
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTerminatedNCT03999515Phase 2Results posted
• A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following SurgeryActive, not recruitingNCT03809000Phase 2Results posted
• A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT03641560Phase 4Results posted
• Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentTerminatedNCT03531827Phase 2Results posted
• ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03480646Phase 1/2Results posted
• Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate CancerTerminatedNCT03478904Phase 1Results posted
• Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerTerminatedNCT03437941Phase 1/2Results posted
• Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on TherapyCompletedNCT03418324Phase 2Results posted
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCActive, not recruitingNCT03395197Phase 3Results posted
• An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCompletedNCT03338790Phase 2Results posted
• ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate CancerTerminatedNCT03300505Phase 1Results posted
• A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate CancerActive, not recruitingNCT03246347Phase 2Results posted
• Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast CancerActive, not recruitingNCT02955394Phase 2Results posted
• Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast CancerCompletedNCT02953860Phase 2Results posted
• Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerCompletedNCT02918968Phase 4Results posted
• Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)CompletedNCT02903160Phase 2Results posted
• A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedNCT02799745Phase 2Results posted
• Enzalutamide for Patients With Androgen Receptor Positive Salivary CancersActive, not recruitingNCT02749903Phase 2Results posted
• A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT02711956Phase 1/2Results posted
• Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerCompletedNCT02689427Phase 2Results posted
• Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate CancerTerminatedNCT02685267Phase 2Results posted
• Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial CancerCompletedNCT02684227Phase 2Results posted
• A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)CompletedNCT02677896Phase 3Results posted
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02607228Phase 1/2Results posted
• Enzalutamide for Bladder Cancer ChemopreventionTerminatedNCT02605863Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT02528643Phase 2Results posted
• Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate CancerActive, not recruitingNCT02522715Phase 1/2Results posted
• Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate CancerTerminatedNCT02508636Phase 2Results posted
• Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)TerminatedNCT02500901Phase 1Results posted
• Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and DocetaxelTerminatedNCT02491411Not applicableResults posted
• Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT02489123Phase 2Results posted
• Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentCompletedNCT02485691Phase 4Results posted
• A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentTerminatedNCT02441517Phase 4Results posted
• Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate CancerCompletedNCT02430480Phase 2Results posted
• A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)CompletedNCT02384382Phase 2Results posted
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)Active, not recruitingNCT02319837Phase 3Results posted
• Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With EnzalutamideActive, not recruitingNCT02312557Phase 2Results posted
• Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerCompletedNCT02300610Phase 1Results posted
• An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer ParticipantsCompletedNCT02294461Phase 3Results posted
• A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide AloneCompletedNCT02288247Phase 3Results posted
• Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide ResistanceCompletedNCT02286921Phase 2Results posted
• Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate CancerCompletedNCT02278185Phase 2Results posted
• Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate CancerCompletedNCT02215096Phase 1Results posted
• Randomized Salvage Radiation Therapy Plus Enzalutamide Post ProstatectomyCompletedNCT02203695Phase 2Results posted
• A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerCompletedNCT02116582Phase 4Results posted
• Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide TherapyCompletedNCT02099864Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast CancerCompletedNCT02091960Phase 2Results posted
• RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)CompletedNCT02090114Phase 2Results posted
• Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate CancerCompletedNCT02064582Phase 2Results posted
• LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate CancerCompletedNCT02058706Phase 2Results posted
• Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)CompletedNCT02057939Phase 2Results posted
• A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)CompletedNCT02034552Phase 2Results posted
• Enzalutamide + External Beam Rt For ProstateCompletedNCT02028988Phase 2Results posted
• Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedNCT02007512Phase 2Results posted
• Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerCompletedNCT02003924Phase 3Results posted
• Safety Study of Continued Enzalutamide Treatment In Prostate Cancer PatientsCompletedNCT01995513Phase 4Results posted
• A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT01981122Phase 2Results posted
• A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With EnzalutamideCompletedNCT01977651Phase 4Results posted
• Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesCompletedNCT01974765Phase 2Results posted

← Enzalutamide overview